Authors: Perkins, AC Wilson, CG Frier, M Blackshaw, PE Dansereau, RJ Vincent, RM Wenderoth, D Hathaway, S Li, ZQ Spiller, RC

Citation: Ac. Perkins et al., The use of scintigraphy to demonstrate the rapid esophageal transit of theoval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water, INT J PHARM, 222(2), 2001, pp. 295-303

Authors: Perkins, AC Wilson, CG Frier, M Blackshaw, PE Juan, D Dansereau, RJ Hathaway, S Li, Z Long, P Spiller, RC

Citation: Ac. Perkins et al., Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects, ALIM PHARM, 15(1), 2001, pp. 115-121

Authors: Hebden, JM Blackshaw, PE Perkins, AC Wilson, CG Spiller, RC

Citation: Jm. Hebden et al., Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis, ALIM PHARM, 14(2), 2000, pp. 155-161

Authors: Perkins, AC Wilson, CG Frier, M Vincent, RM Blackshaw, PE Dansereau, RJ Juhlin, KD Bekker, PJ Spiller, RC

Citation: Ac. Perkins et al., Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations, INT J PHARM, 186(2), 1999, pp. 169-175

Authors: Kong, MF King, P Macdonald, IA Blackshaw, PE Horowitz, M Perkins, AC Armstrong, E Buchanan, KD Tattersall, RB

Citation: Mf. Kong et al., Euglycaemic hyperinsulinaemia does not affect gastric emptying in Type I and Type II diabetes mellitus, DIABETOLOG, 42(3), 1999, pp. 365-372